title: Evolution of radiation techniques in the treatment of mediastinal lymphoma: from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): a single-centre experience and review of the literature.
abstract: OBJECTIVE
  To evaluate radiation techniques and their toxicity in the treatment of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) with mediastinal disease over a 10-year period.
  
  
  METHODS
  Between 2003 and 2015, 173 patients with Stage I-III nodal lymphoma were treated in our institution: some of these patients were irradiated for HL or NHL with mediastinal disease. Some of the patients were treated by three-dimensional conformal radiotherapy (3DCRT), others by intensity-modulated radiotherapy (IMRT).
  
  
  RESULTS
  We studied 26 males and 43 females with a median age of 26 years. The median follow-up was 43 months. 49 patients were treated by 3DCRT and 20 patients by IMRT. The median dose received by patients treated for NHL was 40 Gy (range: 36-44 Gy), and the median dose received by patients with HL was 30 Gy (range: 30-36 Gy). Between 2003 and 2006, 16 patients were treated by 3DCRT vs 0 patients by IMRT. Between 2007 and 2009, 16 patients received 3DCRT and one patient received IMRT. Between 2010 and 2015, 19 patients received IMRT, and no patients received 3DCRT. 11 of the 20 (55%) patients treated by IMRT and 35 of the 49 (71.4%) patients treated by 3DCRT experienced acute toxicity. Among the patients treated by 3DCRT, one patient experienced Grade 1 radiation pneumonitis and two patients experienced Grade 1 acute mucositis. No late toxicity was observed in patients treated by IMRT.
  
  
  CONCLUSIONS
  Improvement of radiation techniques for HL and NHL appears to have improved acute and late clinical safety. Longer follow-up is necessary to evaluate very late toxicity.
  
  
  CONCLUSIONS
  Improvement of radiation techniques for HL and NHL appears to improve the tolerance.
authors.affiliation: Department of Radiation Oncology, Institut Curie, Paris, France.
authors.forename: Nadia
authors.initials: N
authors.lastname: Besson
authors.affiliation: Department of Radiation Oncology, Institut Curie, Paris, France.
authors.forename: Victor
authors.initials: V
authors.lastname: Pernin
authors.affiliation: Department of Radiation Oncology, Institut Curie, Paris, France.
authors.forename: Sofia
authors.initials: S
authors.lastname: Zefkili
authors.affiliation: Department of Radiation Oncology, Institut Curie, Paris, France.
authors.forename: Youlia M
authors.initials: YM
authors.lastname: Kirova
mesh_terms: D000293:Adolescent; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000532:radiotherapy; D006801:Humans; D021621:Imaging, Three-Dimensional; D053208:Kaplan-Meier Estimate; D008223:Lymphoma / Q000532:radiotherapy*; D008297:Male; D008479:Mediastinal Neoplasms / Q000532:radiotherapy*; D008875:Middle Aged; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal / Q000379:methods*; D050397:Radiotherapy, Intensity-Modulated; D036542:Tomography, Spiral Computed; D016896:Treatment Outcome; D055815:Young Adult